WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super safety” in a small cohort of patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2024.
“The unique biological characteristics of NK cells provide us with alternative to treat SLE with super safety,” Qian Hao, PhD, co-founder and CEO of Rui Therapeutics, told attendees.
Hao presented findings from 22 patients — including 18 women — with active severe and refractory SLE who underwent three doses of KN5501 (Rui